Neuromuscular toxicity in nephrotic patients treated with fluvastatin

Related Experiment Videos

Sanaa Gazarin1, Hassan Abd-El-Hady, Osama Gheith

  • 1Department of Internal Medicine, Urology & Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Journal of Nephrology
|December 24, 2002
PubMed

Insights

Fluvastatin effectively reduces triglycerides and LDL cholesterol in nephrotic patients. This study suggests fluvastatin is safe for long-term use in managing dyslipidemia in this population.

Area of Science:

  • Nephrology
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Nephrotic dyslipidemia is a significant risk factor for atherosclerosis and glomerular disease progression.
  • HMG-CoA reductase inhibitors (statins) are effective in lowering LDL-cholesterol but require long-term safety and efficacy evaluation in nephrotic patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of fluvastatin in treating dyslipidemia in nephrotic patients.
  • To assess clinical, neurophysiological, and laboratory parameters during long-term fluvastatin therapy.

Main Methods:

  • A study involving 21 nephrotic patients treated with fluvastatin.
  • Clinical follow-up, neurophysiological assessments (electromyography - EMG), and laboratory tests were conducted.
  • Lipid profiles, including triglycerides (TG) and LDL-cholesterol, and creatine phosphokinase (CPK) levels were monitored.

Main Results:

  • Significant reductions in TG (33%) and LDL-cholesterol (35%) were observed at three months.
  • No clinical signs of myopathy were reported, and CPK levels remained normal.
  • EMG showed decreased motor unit action potential amplitude and duration in proximal muscles, but not indicative of classic myopathy.

Conclusions:

  • Fluvastatin demonstrates safety for long-term use in nephrotic patients with dyslipidemia.
  • Further research is recommended to investigate the long-term progression of early EMG changes observed during fluvastatin therapy.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...